Skip to main content
TipRanks
Go Ultimate75% OFF

AcouSort AB (ACOU) AI Stock Analysis

0 Followers
SE:ACOU

AcouSort AB

(Nasdaq OMX AB:ACOU)

Select Model
Rating:42Neutral
Price Target:SEK 2.00â–¼(-23.37% Downside)
Action:reiterated
Date:11/13/26

The score is held down primarily by weak financial performance—large operating losses, negative gross profit, and ongoing cash burn alongside shrinking equity—despite some revenue growth and a no-debt balance sheet. Technicals add further pressure, with price trading below all major moving averages and negative momentum signals. Valuation offers limited support because earnings are negative and no dividend yield is provided.

Positive Factors
Revenue GrowthRevenue growth indicates continued commercial activity and customer demand for AcouSort’s offerings. If maintained, a larger revenue base could improve operating leverage and help absorb fixed development costs, supporting progress toward a more sustainable business model over the next several quarters.
Negative Factors
Deeply Negative ProfitabilityNegative gross profit and large operating and net losses show that the current revenue base does not yet support a stable, scalable profit model. Continued losses could restrict internal investment capacity and make financial performance dependent on successful margin improvement.

AcouSort AB (ACOU) vs. iShares MSCI Sweden ETF (EWD)

-40%-20%0%20%40%60%80%SE:ACOU-9.66%EWD+15.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 57.14M
Dividend Yield
―
Average Volume (3M)
36.12K
Price to Earnings (P/E)
-5.2
Beta (1Y)
0.05
Revenue Growth
43.22%
EPS Growth
36.11%
Country
Sweden
Employees
11
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

AcouSort AB Business Overview & Revenue Model

Company Description

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular v...

How the Company Makes Money

AcouSort AB makes money primarily by commercializing its acoustofluidic separation technology to customers who need to integrate cell/particle separation and washing into their instruments or manufacturing workflows. Key revenue streams include: (1)...

AcouSort AB Financial Statement Overview

Summary

Revenue is growing (TTM +7.6% to 7.97m) and losses have narrowed versus prior years, but overall financial quality remains weak due to deeply negative profitability (negative gross profit; EBIT -13.0m; net loss -11.2m) and persistent cash burn (TTM operating cash flow -6.6m; free cash flow -6.9m). Zero reported debt helps reduce solvency risk, yet equity has fallen sharply (to ~9.8m), increasing future funding/dilution risk.

Income Statement

18Very Negative

Balance Sheet

63Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue7.97M6.85M4.74M10.55M4.96M3.01M
Gross Profit-7.90M-14.50M4.77M8.39M2.91M548.00K
EBITDA-12.17M-14.33M-15.89M-16.70M-12.86M-11.46M
Net Income-11.22M-12.15M-15.08M-17.09M-13.21M-12.38M
Balance Sheet
Total Assets21.47M17.89M12.32M34.51M42.66M36.56M
Cash, Cash Equivalents and Short-Term Investments9.48M6.29M3.57M23.99M33.97M31.52M
Total Debt000000
Total Liabilities11.67M1.59M3.86M10.38M22.54M3.54M
Stockholders Equity9.81M16.30M8.46M24.14M20.11M33.02M
Cash Flow
Free Cash Flow-6.91M-17.27M-19.84M-31.77M2.95M-12.23M
Operating Cash Flow-6.58M-16.78M-18.81M-31.56M3.96M-10.92M
Investing Cash Flow-1.39M-488.00K-1.02M-1.16M-1.01M-1.31M
Financing Cash Flow-118.00K18.98M-157.00K22.08M035.63M

AcouSort AB Technical Analysis

Technical Analysis SentimentNegative
Last Price2.61

Price Trends

50DMA3.02Negative
100DMA3.23Negative
200DMA3.33Negative

Market Momentum

MACD-0.10Positive
RSI41.03Neutral
STOCH19.60Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACOU, the sentiment is Negative. The current price of 2.61 is below the 20-day moving average (MA) of 3.16, below the 50-day MA of 3.02, and below the 200-day MA of 3.33, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 41.03 is Neutral, neither overbought nor oversold. The STOCH value of 19.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACOU.

AcouSort AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ACOU against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CEVISE:CEVI83OutperformSEK 4.85B35.2115.23%1.35%1.95%-8.91%
SE:FLUISE:FLUI65NeutralSEK 35.99M7.2534.47%―630.57%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ACOUSE:ACOU42NeutralSEK 57.14M-5.19-76.74%―43.22%36.11%
SE:BICOSE:BICO40UnderperformSEK 1.18B-5.17-28.59%―-5.27%34.38%
SE:IMMNOVSE:IMMNOV39UnderperformSEK 87.23M-0.27-215.44%―148.66%66.30%
SE:QLINEASE:QLINEA38UnderperformSEK 250.12M-1.53-48.10%―33.26%90.73%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%SE:ACOUSE:BICOSE:CEVISE:IMMNOVSE:QLINEASE:FLUIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ACOU and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ACOUAcouSort AB2.61-0.04-1.51%
SE:BICOBICO Group AB Class B15.58-3.15-16.82%
SE:CEVICellaVision AB203.5053.2435.43%
SE:IMMNOVImmunovia AB0.03-0.15-82.97%
SE:QLINEAQ-linea AB12.60-13.46-51.65%
SE:FLUIFluicell AB24.2011.4089.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026